Log in

Relevant bibliographies by topics / Antitumor / Journal articles

To see the other types of publications on this topic, follow the link: Antitumor.

Journal articles on the topic 'Antitumor'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antitumor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Shtemenko, A. V., and N. I. Shtemenko. "Rhenium–platinum antitumor systems." Ukrainian Biochemical Journal 89, no. 2 (2017): 5–30. http://dx.doi.org/10.15407/ubj89.02.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tsung, Kangla, Zhang Xu, Zhang Hui, and TANLUN Research Participants Group. "Survival and Concomitant Antitumor Immunity in Cancer." Medical & Clinical Research 9, no. 12 (2024): 01–17. https://doi.org/10.33140/mcr.09.12.06.

Full text

Abstract:

What determines the survival time in a cancer case? An obvious aspect is the malignancy of the tumor. Based on our clinical observation, this so-called malignancy includes three aspects: 1) The mode of tumor replication, i.e., how rapidly a tumor replicates; 2) The ability to form distant metastasis; and 3) The ability to cause symptoms, often related to the ability to drive local inflammation. But tumor malignancy alone does not seem to correlate with cancer survival. Another factor contributing equally critical or even more critical to cancer survival is often ignored. It is the status of ho

APA, Harvard, Vancouver, ISO, and other styles

3

Tsung, Kangla. "Survival and Concomitant Antitumor Immunity in Cancer." Journal of Clinical & Experimental Immunology 9, no. 2 (2024): 01–19. https://doi.org/10.33140/jcei.09.02.05.

Full text

Abstract:

What determines the survival time in a cancer case? An obvious aspect is the malignancy of the tumor. Based on our clinical observation, this so-called malignancy includes three aspects: 1) The mode of tumor replication, i.e., how rapidly a tumor replicates; 2) The ability to form distant metastasis; and 3) The ability to cause symptoms, often related to the ability to drive local inflammation. But tumor malignancy alone does not seem to correlate with cancer survival. Another factor contributing equally critical or even more critical to cancer survival is often ignored. It is the status of ho

APA, Harvard, Vancouver, ISO, and other styles

4

Didenko, G. V. "ANTITUMOR AND ANTIMETASTATIC EFFICIENCY OF ANTITUMOR VACCINE AND AMIXIN COMBINED ACTION IN MICE WITH LEWIS LUNG CARCINOMA." Biotechnologia Acta 9, no. 3 (2016): 76–83. http://dx.doi.org/10.15407/biotech9.03.076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Maksimov, Maksim Leonidovich, and Malika Anarbekovna Ismailova. "Adverse reactions during chemotherapy: skin toxicity." Vrač skoroj pomoŝi (Emergency Doctor), no. 9 (September 1, 2020): 28–64. http://dx.doi.org/10.33920/med-02-2009-01.

Full text

Abstract:

Chemotherapy of oncological diseases is associated with high toxicity. The occurrence of various toxic reactions during the use of antitumor drugs is explained by the fact that most antitumor medicines are not strictly specific, therefore, their effect can extend not only to tumor cells, but also to normal cells, especially to tissues with rapid proliferation. All antitumour agents have skin toxicity in one form or another. However, for some chemotherapeutic agents, skin toxicity is a kind of «reflection» of certain mechanisms of drugs action, and, in most cases, the severity of dermatological

APA, Harvard, Vancouver, ISO, and other styles

6

Torres, Nicolas, María Victoria Regge, Florencia Secchiari, et al. "Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein." Journal for ImmunoTherapy of Cancer 8, no. 1 (2020): e000233. http://dx.doi.org/10.1136/jitc-2019-000233.

Full text

Abstract:

BackgroundNatural killer and cytotoxic CD8+T cells are major players during antitumor immunity. They express NKG2D, an activating receptor that promotes tumor elimination through recognition of the MHC class I chain-related proteins A and B (MICA and MICB). Both molecules are overexpressed on a great variety of tumors from different tissues, making them attractive targets for immunotherapy. However, tumors shed MICA and MICB, and the soluble forms of both (sMICA and sMICB) mediate tumor-immune escape. Some reports indicate that anti-MICA antibodies (Ab) can promote the restoration of antitumor

APA, Harvard, Vancouver, ISO, and other styles

7

Asche, Christian, and Martine Demeunynck. "Antitumor Carbazoles." Anti-Cancer Agents in Medicinal Chemistry 7, no. 2 (2007): 247–67. http://dx.doi.org/10.2174/187152007780058678.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Scuderi, N., and M. G. Onesti. "Antitumor Agents." Annals of Plastic Surgery 32, no. 1 (1994): 39–44. http://dx.doi.org/10.1097/00000637-199401000-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

NISHIKAWA, KIYOHIRO, CHIEKO SHIBASAKI, KATSUTOSHI TAKAHASHI, TERUYA NAKAMURA, TOMIO TAKEUCHI, and HAMAO UMEZAWA. "Antitumor activity of spergualin, a novel antitumor antibiotic." Journal of Antibiotics 39, no. 10 (1986): 1461–66. http://dx.doi.org/10.7164/antibiotics.39.1461.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Akima, Kazuo, Hisashi Ito, Yuhei Iwata, et al. "Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity." Journal of Drug Targeting 4, no. 1 (1996): 1–8. http://dx.doi.org/10.3109/10611869609046255.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Gomi, Katsushige, Eiji Kobayashi, Katsunori Miyoshi, et al. "Anticellular and Antitumor Activity of Duocarmycins, Novel Antitumor Antibiotics." Japanese Journal of Cancer Research 83, no. 1 (1992): 113–20. http://dx.doi.org/10.1111/j.1349-7006.1992.tb02360.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Zhang, Lingbing, Dongdong Feng, Lynda X. Yu, Kangla Tsung, and Jeffrey A. Norton. "Preexisting antitumor immunity augments the antitumor effects of chemotherapy." Cancer Immunology, Immunotherapy 62, no. 6 (2013): 1061–71. http://dx.doi.org/10.1007/s00262-013-1417-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Shtemenko, N. I., D. E. Kytova, O. V. Berzenina, O. I. Hrabovska, and A. V. Shtemenko. "New formulation and activity of rhenium-platinum antitumor system." Ukrainian Biochemical Journal 94, no. 3 (2022): 92–98. http://dx.doi.org/10.15407/ubj94.03.092.

Full text

Abstract:

Two-component Rhenium-Platinum system (Re-Pt system) is based on administration of a cluster dirhenium(III) compound and cisplatin to tumor bearing animals followed by a significant antitumor effect and decreased toxic effect of cisplatin on normal cells. The aim of this work was to obtain solid lipid nanoparticles (SLN) from surface lipids (waxes) of Chelidonium majus L. (Papaveraceae) leaves and to estimate whether capsulation of dirhenium(III) as a component of the Re-Pt system into SLN will affect its antitumor activity and red blood cells (RBC) morphology in a rat model of Guerin’s carcin

APA, Harvard, Vancouver, ISO, and other styles

14

KOSUGE, TAKUO, MASAMI YOKOTA, KIYOSHI SUGIYAMA, TOSUKE YAMAMOTO, MUYUN NI, and SHUCHANG YAN. "Studies on Antitumor Activities and Antitumor Principles of Chinese Herbs. I. Antitumor Activities of Chinese Herbs." YAKUGAKU ZASSHI 105, no. 8 (1985): 791–95. http://dx.doi.org/10.1248/yakushi1947.105.8_791.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Villa-Pulgarin, Janny A., Constain H. Salamanca, Jose Oñate-Garzón, and Ruben E. Varela-M. "Antitumor Activity In Vitro Provided by N-Alkyl-Nitroimidazole Compounds." Open Medicinal Chemistry Journal 14, no. 1 (2020): 45–48. http://dx.doi.org/10.2174/1874104502014010045.

Full text

Abstract:

Background: Cancer is one of the most common diseases in the world, with over 18 million new cases estimated in 2018. Many of the drugs used for cancer can have significant adverse effects and variable effectiveness. Nitroimidazoles are prodrugs that usually have shown antimicrobial activity specifically antiparasitic. However, its antitumor activity in vitro has barely been explored. Objective: The aim of this study is to determine the influence of the length of the substituted N-alkyl chain in the imidazole ring on the antitumor activity in vitro. Methods: Four nitroimidazoles were obtained

APA, Harvard, Vancouver, ISO, and other styles

16

Sánchez-Quesada, Cristina, Francisco Gutiérrez-Santiago, Carmen Rodríguez-García, and José J. Gaforio. "Synergistic Effect of Squalene and Hydroxytyrosol on Highly Invasive MDA-MB-231 Breast Cancer Cells." Nutrients 14, no. 2 (2022): 255. http://dx.doi.org/10.3390/nu14020255.

Full text

Abstract:

Several studies relate Mediterranean diet and virgin olive oil (VOO) intake with lower risk of several chronic diseases, including breast cancer. Many of them described antitumor properties of isolated minor compounds present in VOO, but beneficial properties of VOO arise from the effects of all its compounds acting together. The aim of the present study was to test the antitumor effects of two minor compounds from VOO (hydroxytyrosol (HT) and squalene (SQ)) on highly metastatic human breast tumor cells (MDA-MB-231) when acting in combination. Both isolated compounds were previously analyzed w

APA, Harvard, Vancouver, ISO, and other styles

17

Pérez, Marina, Berta Buey, Pilar Corral, David Giraldos, and Eva Latorre. "Microbiota-Derived Short-Chain Fatty Acids Boost Antitumoral Natural Killer Cell Activity." Journal of Clinical Medicine 13, no. 13 (2024): 3885. http://dx.doi.org/10.3390/jcm13133885.

Full text

Abstract:

Background: The intestinal microbiota can regulate numerous host functions, including the immune response. Through fermentation, the microbiota produces and releases microbial metabolites such as short-chain fatty acids (SCFAs), which can affect host homeostasis. There is growing evidence that the gut microbiome can have a major impact on cancer. Specific gut microbial composition and metabolites are associated with tumor status in the host. However, their effects on the antitumor response have scarcely been investigated. Natural killer (NK) cells play an important role in antitumor immunity d

APA, Harvard, Vancouver, ISO, and other styles

18

Lin, J. Y. "Antitumor Protein: Abrin." Journal of Toxicology: Toxin Reviews 13, no. 3 (1994): 219–28. http://dx.doi.org/10.3109/15569549409089961.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Ferrarelli, L. K. "Engineering antitumor activity." Science 353, no. 6307 (2016): i—1510. http://dx.doi.org/10.1126/science.353.6307.1509-i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Rusk, Nicole. "Antitumor T cells." Nature Methods 16, no. 1 (2018): 19. http://dx.doi.org/10.1038/s41592-018-0271-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Foley, John F. "Highlight: Antitumor strategies." Science Signaling 10, no. 500 (2017): eaaq1397. http://dx.doi.org/10.1126/scisignal.aaq1397.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Fiallo, Marina M. L., Henryk Kozlowski, and Arlette Garnier-Suillerot. "Mitomycin antitumor compounds." European Journal of Pharmaceutical Sciences 12, no. 4 (2001): 487–94. http://dx.doi.org/10.1016/s0928-0987(00)00200-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

KONISHI, Masataka. "Novel antitumor antibiotics." Kagaku To Seibutsu 26, no. 2 (1988): 90–101. http://dx.doi.org/10.1271/kagakutoseibutsu1962.26.90.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Krapcho, A. P., and E. Menta. "Antitumor aza-anthrapyrazoles." Drugs of the Future 22, no. 6 (1997): 641. http://dx.doi.org/10.1358/dof.1997.022.06.418670.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Nagamura, Satoru, and Hiromitsu Saito. "Antitumor antibiotics: Duocarmycins." Chemistry of Heterocyclic Compounds 34, no. 12 (1998): 1386–405. http://dx.doi.org/10.1007/bf02317808.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Motohashi, Noboru, Lester A. Mitscher, and Roger Meyer. "Potential antitumor phenoxazines." Medicinal Research Reviews 11, no. 3 (1991): 239–94. http://dx.doi.org/10.1002/med.2610110302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Houlihan, William J., Matthias Lohmeyer, Paul Workman, and Seung H. Cheon. "Phospholipid antitumor agents." Medicinal Research Reviews 15, no. 3 (1995): 157–223. http://dx.doi.org/10.1002/med.2610150302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Crompton, Joseph G., David Clever, Raul Vizcardo, Mahendra Rao, and Nicholas P. Restifo. "Reprogramming antitumor immunity." Trends in Immunology 35, no. 4 (2014): 178–85. http://dx.doi.org/10.1016/j.it.2014.02.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

ISHIZEKI, SEIJI, MARI OHTSUKA, KAZUHIKO IRINODA, KEN-ICHI KUKITA, KATSUHIKO NAGAOKA, and TOSHIAKI NAKASHIMA. "Azinomycins A and B, new antitumor antibiotics. III. Antitumor activity." Journal of Antibiotics 40, no. 1 (1987): 60–65. http://dx.doi.org/10.7164/antibiotics.40.60.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

ZHEN, YONG-SU, XIU-YING MING, BIN YU, TOSHIO OTANI, HITOSHI SAITO, and YUJI YAMADA. "A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity." Journal of Antibiotics 42, no. 8 (1989): 1294–98. http://dx.doi.org/10.7164/antibiotics.42.1294.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Kalechman, Y., A. Shani, S. Dovrat, et al. "The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma." Journal of Immunology 156, no. 3 (1996): 1101–9. http://dx.doi.org/10.4049/jimmunol.156.3.1101.

Full text

Abstract:

Abstract The immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate (AS101) has been shown to possess antitumoral properties in several murine models. In the present study, we demonstrate a synergistic in vivo antitumor effect of AS101 and Taxol against early stage Madison 109 lung adenocarcinoma. Treatment with optimal doses of Taxol (25 and 17 mg/kg) and AS101 (0.5 mg/kg) resulted in 66.6 and 43.3% cures. We propose that the antitumor effect is the result of both a direct and indirect effect of the drugs on tumor cells. AS101 and Taxol directly inhibited clonogenicity of M109 cells

APA, Harvard, Vancouver, ISO, and other styles

32

Vargas-Castro, Karen C., Ana M. Puebla Pérez, Irma I. Rangel-Salas, et al. "Antitumor Effect of Zwitterions of Imidazolium Derived from L-methionine in BALB/c Mice with Lymphoma L5178Y." Medicinal Chemistry 17, no. 1 (2020): 33–39. http://dx.doi.org/10.2174/1573406415666191206093754.

Full text

Abstract:

Background: In the therapy of cancer, several treatments have been designed using nanomaterials, among which gold nanoparticles (AuNPs) have been featured as a promising antitumoral agent. Our research group has developed the synthesis of gold nanoparticles L-AuNPs and D-AuNPs stabilized with zwitterions of imidazolium (L-1 and D-1) derived from L-methionine and D-methionine. Because the stabilizer agent is chiral, we observed through circular dichroism that AuNPs also present chirality; such chirality as well as the fact that the stabilizing agent contains fragments of methionine and imidazol

APA, Harvard, Vancouver, ISO, and other styles

33

Wang, Xinmin, Ying Wang, Jialiang Hu, and Hanmei Xu. "An antitumor peptide RS17‐targeted CD47, design, synthesis, and antitumor activity." Cancer Medicine 10, no. 6 (2021): 2125–36. http://dx.doi.org/10.1002/cam4.3768.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

SMITKA, T. A., R. H. BUNGE, J. H. WILTON, et al. "PD 116,152, a new phenazine antitumor antibiotic. Structure and antitumor activity." Journal of Antibiotics 39, no. 6 (1986): 800–803. http://dx.doi.org/10.7164/antibiotics.39.800.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Huang, Haochao, Haiwei Wu, Yongrui Huang, Shuangying Zhang, Yuetwai Lam, and Ningjian Ao. "Antitumor activity and antitumor mechanism of triphenylphosphonium chitosan against liver carcinoma." Journal of Materials Research 33, no. 17 (2018): 2586–97. http://dx.doi.org/10.1557/jmr.2018.255.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Wang, Yongfeng, Malcolm F. G. Stevens, Tze-ming Chan, et al. "Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide." Journal of Organic Chemistry 62, no. 21 (1997): 7288–94. http://dx.doi.org/10.1021/jo970802l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

NISHIMURA, MAKOTO, HIROHISA NAKADA, IKUO KAWAMURA, et al. "A new antitumor antibiotic, FR900840. III. Antitumor activity against experimental tumors." Journal of Antibiotics 42, no. 4 (1989): 553–57. http://dx.doi.org/10.7164/antibiotics.42.553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gajendran, Nithya, David Quiceno-Torress, Xintang Li, et al. "Abstract 3144: Selective HDAC10 inhibitor enhances innate antitumor immunity." Cancer Research 85, no. 8_Supplement_1 (2025): 3144. https://doi.org/10.1158/1538-7445.am2025-3144.

Full text

Abstract:

Abstract Most anticancer therapies aim to target specific mechanisms that regulate or potentially inhibit the proliferation and survival of cancer cells. Macrophages play a crucial role in the tumor microenvironment (TME), exhibiting both pro and antitumoral functions depending on the polarization state. Our lab focuses on transforming the immune suppressive TME into an antitumoral environment, explicitly enhancing the proinflammatory M1 macrophage phenotype using HDAC inhibitors. Many research studies have shown the aberrant expression of HDAC10 in cancer and various pathologies. However, the

APA, Harvard, Vancouver, ISO, and other styles

39

Yu, Wang, and Li Ling. "Research Progress of Antitumor Activity by Baicalin and Baicalein." International Journal of Sciences Volume 8, no. 2019-06 (2019): 11–14. https://doi.org/10.5281/zenodo.3350775.

Full text

Abstract:

Baicalin and its aglycon, baicalein, are flavonoids present from Scutellaria baicalensis Georgi. Baicalin generally inhibits tumor cells by inducing apoptosis and arresting growth, while baicalein suppresses by regulating autophagy. Certain signaling pathways and regulating factors are involved among the induced-apoptosis and autophagy progress. In suppressing growth, baicalin and baicaein inhibit angiogenesis or induce cell cycle arrest at S phase against proliferation, migration and differentiation. The present agents against tumor still have related side effects. Therefore, the natural and

APA, Harvard, Vancouver, ISO, and other styles

40

Zheng, Zhi-Zhong, Liang-Hua Chen, Shao-Song Liu, et al. "Bioguided Fraction and Isolation of the Antitumor Components fromPhyllanthus niruriL." BioMed Research International 2016 (2016): 1–7. http://dx.doi.org/10.1155/2016/9729275.

Full text

Abstract:

Phyllanthus niruriL., a well-known medicinal plant, has been used as a folk antitumor remedy in the worldwide scale. However, the antitumor components inP. nirurihave not been reported. In order to verify the antitumor components ofP. niruriand the plants which have the high content of these components, we isolated the antitumor components with bioguided fraction and isolation, by different chromatographic methods from the ethyl acetate fraction ofP. niruri., and identified them as ethyl brevifolincarboxylate and corilagin by1H-NMR,13C-NMR, 2D-NMR, and mass spectrometric analyses. Cell cytotox

APA, Harvard, Vancouver, ISO, and other styles

41

Gong, Ting, Min Deng, Haibo Lei, et al. "The influence of clinical pharmacist-directed PDCA and DRG on the hospital’s antitumor treatments and safety management." Indian Journal of Cancer 61, no. 3 (2024): 654–61. https://doi.org/10.4103/ijc.ijc_266_24.

Full text

Abstract:

Abstract Background: To assess the impact of the clinical pharmacist-directed PDCA+DRG approach on antitumor treatments and safety management within a hospital setting, specifically focusing on medical expenses, the utilization rate of restricted-level antitumor drugs, and the allocation of expenditure on antitumor drugs and adjunctive medications across different cancer types. Methods: The retrospective study involved a comparative analysis between a control group (n = 105) and a PDCA+DRG group (n = 102) across various cancer types. On the basis of the medical insurance policy, the control gr

APA, Harvard, Vancouver, ISO, and other styles

42

Kato, Taketo, Johannes F. Fahrmann, Samir M. Hanash, and Jody Vykoukal. "Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy." Cells 9, no. 6 (2020): 1518. http://dx.doi.org/10.3390/cells9061518.

Full text

Abstract:

Extracellular vesicles (EVs) are increasingly understood to participate directly in many essential aspects of host antitumor immune response. Tumor- and immune-cell-derived EVs function in local and systemic contexts with roles in immune processes including cancer antigen conveyance, immune cell priming and activation, as well as immune escape. Current practice of cancer immunotherapy has de facto focused on eliciting T-cell-mediated cytotoxic responses. Humoral immunity is also known to exert antitumor effects, and B cells have been demonstrated to have functions that extend beyond antibody p

APA, Harvard, Vancouver, ISO, and other styles

43

Scheller, S., W. Krol, K. Skirmuntt, G. Zydowicz, and J. Shani. "Antitumoral Effect of Bleomycin + Dolomite Combination Treatment, in Mice Bearing Ehrlich Ascites Carcinoma." Zeitschrift für Naturforschung C 48, no. 9-10 (1993): 818–20. http://dx.doi.org/10.1515/znc-1993-9-1023.

Full text

Abstract:

Abstract Dolomite, a mineral composed of magnesium and calcium carbonates, potentiates the antitumoral activity of bleomycin: While 40 days after inoculation, no mice survived the Ehrlich ascites tumor burden, 44% of them survived it after bleomycin treatment, and 63% after a simultaneous treatment of bleomycin and dolomite. The beneficial antitumor effect of dolomite is probably related to its high content (12.8%) of magnesium

APA, Harvard, Vancouver, ISO, and other styles

44

Chengzhi, Wang, Liu Yifan, Zhang Xiaoqing, Liu Peimin, and Li Dongdong. "Research progress of natural products targeting tumor-associated macrophages in antitumor immunity: A review." Medicine 103, no. 46 (2024): e40576. http://dx.doi.org/10.1097/md.0000000000040576.

Full text

Abstract:

As an important innate immune cell in the body, macrophages have a strong ability to phagocytic tumor cells and maintain the innate immune response. Tumor-associated macrophages play a more prominent role in regulating tumor immunity and are currently an important target of antitumor immunity. As a new type of antitumor therapy, tumor immunotherapy has great potential, combined chemotherapy, targeting and other therapeutic means can significantly enhance the antitumor therapy effect. At present, a number of natural products have been proved to have significant immunomodulatory and antitumor ef

APA, Harvard, Vancouver, ISO, and other styles

45

Germeau, Catherine, Wenbin Ma, Francesca Schiavetti, et al. "High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens." Journal of Experimental Medicine 201, no. 2 (2005): 241–48. http://dx.doi.org/10.1084/jem.20041379.

Full text

Abstract:

After vaccination of melanoma patients with MAGE antigens, we observed that even in the few patients showing tumor regression, the frequency of anti-vaccine T cells in the blood was often either undetectable or &lt;10−5 of CD8 T cells. This frequency being arguably too low for these cells to be sole effectors of rejection, we reexamined the contribution of T cells recognizing other tumor antigens. The presence of such antitumor T cells in melanoma patients has been widely reported. To begin assessing their contribution to vaccine-induced rejection, we evaluated their blood frequency in fiv

APA, Harvard, Vancouver, ISO, and other styles

46

Takaku, Shun, Masumi Shimizu, and Rimpei Morita. "CD8+ T Cell-Mediated Therapeutic Antitumor Effect of an Herbal Mixture Containing Ganoderma lucidum." Evidence-Based Complementary and Alternative Medicine 2023 (April 28, 2023): 1–11. http://dx.doi.org/10.1155/2023/9630816.

Full text

Abstract:

Although Kampo—a traditional Japanese herbal medicine—contributes in the control of tumor growth in vivo in experimental animals, most of the antitumor effects are prophylactic and not therapeutic. In this study, we determined whether oral administration of an herbal mixture containing Ganoderma lucidum (WTMCGEP; Wisteria floribunda, Trapae fructus, Myristica fragrans, Coicis semen, Ganoderma lucidum, Elfvingia applanata, and Punica granatum), anecdotally used in Japan for the palliative care of patients with cancer, exhibits a therapeutic effect on tumor growth in vivo in a hypodermic murine

APA, Harvard, Vancouver, ISO, and other styles

47

Bruni, Sofia, Camila Jencquel, Martin A. Rivas, Roxana Schillaci, and Maria F. Mercogliano. "Abstract 882: Soluble TNF blockade enhances trastuzumab-deruxtecan innate antitumor immune response and type-I IFN signalling in HER2-positive breast cancer." Cancer Research 85, no. 8_Supplement_1 (2025): 882. https://doi.org/10.1158/1538-7445.am2025-882.

Full text

Abstract:

Since DESTINY-Breast03 results where trastuzumab-deruxtecan (T-DXd) showed remarkable overall survival improvement, this drug is used to treat patients with unresectable or metastatic HER2-positive (HER2+) breast cancer who have received prior anti-HER2-based regimen. One antitumor mechanism of T-DXd is attributed to DXd inhibition of topoisomerase I in the tumor cells that internalized the drug, and to the bystander effect of DXd on neighbor tumor cells. Reports describe that topoisomerase I inhibitors produce DNA fragmentation, stimulating cGAS/STING pathway and producing type-I IFN, a key m

APA, Harvard, Vancouver, ISO, and other styles

48

Zhang, Hui, Zhaohui Zhu, Faya Zhang, and Samantha Modrak. "Reconstitution of iNKT cells enhances antitumor immunity through liver education of iNKT cells and modulation of tumor microenvironment." Journal of Immunology 202, no. 1_Supplement (2019): 134.10. http://dx.doi.org/10.4049/jimmunol.202.supp.134.10.

Full text

Abstract:

Abstract Invariant natural killer (iNKT) cells are a specific population of T cells that functionally are more like innateimmune regulatory cells and play important roles in antitumor immunity. It is reported that reconstitution of iNKT cells enhances antitumor immunity in human and mice, however, the underlying mechanism is not known. Using thymocytes and splenocytes to reconstitute iNKT cells in iNKT KO mice, we found that reconstitution of iNKT cells dramatically inhibits tumor development, progression and metastasis, and increases the survival of tumor-bearing mice. Most of the transferred

APA, Harvard, Vancouver, ISO, and other styles

49

Dimopoulos, Meletios-Athanassios, Constantine S. Mitsiades, Kenneth C. Anderson, and Paul G. Richardson. "Tanespimycin as Antitumor Therapy." Clinical Lymphoma Myeloma and Leukemia 11, no. 1 (2011): 17–22. http://dx.doi.org/10.3816/clml.2011.n.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Jones, G., and F. Fouad. "Designed Enediyne Antitumor Agents." Current Pharmaceutical Design 8, no. 27 (2002): 2415–40. http://dx.doi.org/10.2174/1381612023392810.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!